Janumet XR (Sitagliptin Phos/Metformin HCl) Patent Expiration, LOE Window & CMS Spending
Janumet XR (Sitagliptin Phos/Metformin HCl) by Merck & Co.: FDA Orange Book core substance LOE 2027-05-24, 1 AB generics, $401.1M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Merck & Co. |
| FDA Application & Pathway | N202270 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | 2027-05-24 |
| Last Listed Patent or Exclusivity Date | 2027-05-24 |
| Orange Book Patents (*PED Extensions) | 2 patents (1 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $401.1M |
| 2024 Medicare Part D Spend | $358.0M |
| 2024 Medicaid Spend | $43.1M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.